EGFR and non-small cell lung carcinoma: Recent studies indicate that HER3 contributes to drug resistance in EGFR-TKIs in NSCLC due to activation of the PI3K pathway and the overexpression of pro-growth and anti-apoptotic signals via the AKT pathway [30].